DULOXETINE AND FLECAINIDE

Duloxetine (a moderate inhibitor of CYP2D6) may inhibit the metabolism of flecainide (a substrate for CYP2D6), increasing the risk of flecainide adverse effects.
The manufacturer advises caution.